Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage gene therapy company, will present at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:00 pm PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage gene therapy company, will present at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 1:00 pm PT. The presentation will focus on their innovative gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema. Investors can access a live webcast under the Events section on the company's website, with an archived version available for 30 days post-event.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was -2.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 1:00 pm PT.
A live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. The archived webcast will be available on the Adverum website following the presentation for 30 days.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-304-3892
Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
1-646-876-5196
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.